Companies ›Industrials ›PBSV

PBSV — OTC IT Services & Consulting

Pharma-Bio Serv, Inc.

$0,42

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

9,7M USD

P/E

—

EV / Rev

0,3x

Div yield

—

Op margin

-7,1 %

ROE

-1,0 %

Net margin

-1,1 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,58

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Pharma-Bio Serv, Inc. is classified under Technology / IT Services & Consulting and appears profitable on the latest normalized snapshot.

Business. Pharma-Bio Serv, Inc. (PBSV) is an IT services and consulting firm that provides IT consulting and other services. The company is headquartered in the United States and trades on the OTC market under the ticker symbol PBSV. Specific details regarding operating segments and geographic revenue mix are not available.

Classification70 %

SectorTechnology

Business sectorSoftware & IT Services

Industry groupIT Services & Consulting

ActivityIT Consulting & Other Services

Generated · rules-based

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-1,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning PBSV.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials · THIS SECTOR−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to PBSV. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Pharma-Bio Serv, Inc. (PBSV) is an IT services and consulting firm that provides IT consulting and other services. The company is headquartered in the United States and trades on the OTC market under the ticker symbol PBSV. Specific details regarding operating segments and geographic revenue mix are not available.

Classification70 %

SectorTechnology

Business sectorSoftware & IT Services

Industry groupIT Services & Consulting

ActivityIT Consulting & Other Services

AI synthesis

GENERATED

Pharma-Bio Serv, Inc. (PBSV) is currently classified as IT Consulting & Other Services within IT Services & Consulting (Technology). Classification confidence: 0.70 (rule-based classification). Capital structure on the latest snapshot: total assets 11,499,398 USD, total equity 10,454,229, short-term debt 0, long-term debt 0. Net cash position is approximately 6,680,834 USD. Self-calculated market cap is 9,622,961 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 4,997,909, gross profit 1,624,415, operating income 50,141, net income 265,846. Return on equity ~-1.0%. Return on assets ~-0.9%. Operating-cash-flow to net-income ratio is 2.14. Risk profile from automated assessment: liquidity risk low, dilution risk low. Flags: No immediate filing-based liquidity or dilution flags were detected.. Recent news context: [TRIGGER] ha_price_52w: ha_price_52w fired on PBSV — basis={'bars_asof': '2026-07-24', 'basis_date': '2026-07-24', 'quote_as_of': None, 'basis_source': 'broker_bars', 'staleness_days': 1}; source=ha_price_level; ticker=PBSV; metrics={'close': 0.4225, 'volume': 2500, 'bars_asof': '2026-07-24', 'bars_used': 259, 'direction': 'low', 'basis_date': '2026-07-24', 'basis_source': 'broker_bars', 'volume_ratio': 2.027, 'avg_volume_20': 1233.33, 'prior_52w_low': 0.4626, 'prior_52w_high': 0.69, 'staleness_days': 1, 'volume_confirmed': True}; summary=PBSV printed a new 52-week low on elevated volume (x2.027); detector=broker_read_plane; severity=medium; company_id=da0d859a-9e60-4ac3-87e3-26b5f5b2ed7c; transition={'to': 'low_break', 'from': 'inside'}; watcher_kind=ha_price_52w; event_context=PBSV printed a new 52-week low on elevated volume (x2.027); contributing_watchers=ha_price_52w (source=ha_price_level; url=plv:52w:low:2026-07-24). Additional context: ha_price_52w: basis={'bars_asof': '2026-07-24', 'basis_date': '2026-07-24', 'quote_as_of': None, 'basis_source': 'broker_bars', 'staleness_days': 1}; source=ha_price_level; ticker=PBSV; metrics={'close': 0.4225, 'volume': 2500, 'bars_asof': '2026-07-24', 'bars_used': 259, 'direction': 'low', 'basis_date': '2026-07-24', 'basis_source': 'broker_bars', 'volume_ratio': 2.027, 'avg_volume_20': 1233.33, 'prior_52w_low': 0.4626, 'prior_52w_high': 0.69, 'staleness_days': 1, 'volume_confirmed': True}; summary=PBSV printed a new 52-week low on elevated volume (x2.027); detector=broker_read_plane; severity=medium; company_id=da0d859a-9e60-4ac3-87e3-26b5f5b2ed7c; transition={'to': 'low_break', 'from': 'inside'}; watcher_kind=ha_price_52w; event_context=PBSV printed a new 52-week low on elevated volume (x2.027); contributing_watchers=ha_price_52w.

Key takeaways

Return on equity is about -1.0%.
Debt to equity is about 0.0x.
[TRIGGER] ha_price_52w: ha_price_52w fired on PBSV — basis={'bars_asof': '2026-07-24', 'basis_date': '2026-07-24', 'quote_as_of': None, 'basis_source': 'broker_bars', 'staleness_days': 1}; source=ha_price_level; ticker=PBSV; metrics={'close': 0.4225, 'volume': 2500, 'bars_asof': '2026-07-24', 'bars_used': 259, 'direction': 'low', 'basis_date': '2026-07-24', 'basis_source': 'broker_bars', 'volume_ratio': 2.027, 'avg_volume_20': 1233.33, 'prior_52w_low': 0.4626, 'prior_52w_high': 0.69, 'staleness_days': 1, 'volume_confirmed': True}; summary=PBSV printed a new 52-week low on elevated volume (x2.027); detector=broker_read_plane; severity=medium; company_id=da0d859a-9e60-4ac3-87e3-26b5f5b2ed7c; transition={'to': 'low_break', 'from': 'inside'}; watcher_kind=ha_price_52w; event_context=PBSV printed a new 52-week low on elevated volume (x2.027); contributing_watchers=ha_price_52w (source=ha_price_level; url=plv:52w:low:2026-07-24)
The carrying value of the Company's financial instruments, cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature.
10 Table of Contents The Company follows guidance from the Financial Accounting Standards Board (“FASB”) related to Accounting for Uncertainty in Income Taxes, which includes a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-04-30

Q1 2026 · Quarter highlights

Revenue $5.0M; Operating income $50.1k.

Revenue$5.0M

Operating income$50.1k

Net income$265.8k

Free cash flow-$760.2k

EPS—

Operating cash flow-$755.5k

Financials

Income statement

Revenue$5.0M

Gross profit$1.6M

Operating income$50.1k

Net income$265.8k

Margins

Gross margin32.5%

Operating margin1.0%

Net margin5.3%

FCF margin-15.2%

Balance sheet

Total assets$11.5M

Total liabilities$1.0M

Total equity$10.5M

Cash & equivalents—

Long-term debt—

Cash flow

Operating cash flow-$755.5k

CapEx$4.7k

Free cash flow-$760.2k

SBC$17.2k

P&L flow · revenue → net income

Highlights

▍Revenue $5.0M
▍Operating income $50.1k
▍Net margin 5.3%

Valuation FY

Market price

$0,42

Market cap

$9.6M

Enterprise valueⓘ

$2.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

0.3x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.9x

P / Tangible bookⓘ

0.9x

Tangible book

$10.5M

Net cashⓘ

$6.7M

Current ratioⓘ

10.8

Debt / equityⓘ

—

ROAⓘ

-0.9%

ROEⓘ

-1.0%

Cash conversionⓘ

214.0%

CapEx / revenueⓘ

0.1%

SBC / revenueⓘ

0.4%

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs PBSV · multiples and returns

V—

VISA INC.

$366,11

—

P/E

—

— vs self

Div yield

0,2 %

— vs self

ROE

56,2 %

+57,2 vs self

PYPL—

PAYPAL HOLDINGS, INC.

$57,85

53,2B USD

P/E

9,8x

— vs self

Div yield

0,2 %

— vs self

ROE

26,1 %

+27,1 vs self

XYZ—

Block Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

FISV—

FISERV, INC.

$54,50

29,2B USD

P/E

7,9x

— vs self

Div yield

—

— vs self

ROE

13,3 %

+14,2 vs self

J—

Jacobs Solutions Inc

$138,72

16,5B USD

P/E

50,2x

— vs self

Div yield

—

— vs self

ROE

8,0 %

+8,9 vs self

CTAS—

Cintas Corp

$202,12

82,2B USD

P/E

39,9x

— vs self

Div yield

0,9 %

— vs self

ROE

37,9 %

+38,8 vs self

ABM—

Abm Industries Inc

$48,74

2,9B USD

P/E

17,8x

— vs self

Div yield

2,2 %

— vs self

ROE

9,1 %

+10,0 vs self

GPN—

Global Payments Inc

$86,19

20,4B USD

P/E

—

— vs self

Div yield

1,3 %

— vs self

ROE

-3,1 %

-2,1 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-7,1 %Bottom quartile

Net Margin-1,1 %Below median

ROE-1,0 %Below median

Capex / Rev0,1 %Above P75

D/E0,00Above P75

Cash Conv2,14Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Pharma-Bio Serv, Inc. company facts · 2026-07-26
Pharma-Bio Serv, Inc. 10-Q 2026-06-15 · 2026-07-26
Pharma-Bio Serv, Inc. 10-Q 2026-03-17 · 2026-07-26
Pharma-Bio Serv, Inc. 10-K 2026-01-29 · 2026-07-26
Pharma-Bio Serv, Inc. 10-Q 2025-09-15 · 2026-07-26
ha_price_52w fired on PBSV · 2026-07-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

PBSVCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): -14.6%Derived (calculated)
Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -18.9%Derived (calculated)
Total assets (YoY) (2026-01-31 vs 2025-01-31): -15.7%Derived (calculated)
Debt-to-equity (FY 2026-01-31): 0.32xDerived (calculated)
Current ratio (FY 2026-01-31): 4.03xDerived (calculated)
Shareholders' equity (annual): USD 10.24MSEC XBRL filing
Shares outstanding (annual): 22.9MSEC XBRL filing
Total assets (annual): USD 13.55MSEC XBRL filing
Current assets (annual): USD 13.32MSEC XBRL filing
Total liabilities (annual): USD 3.31MSEC XBRL filing
Current liabilities (annual): USD 3.31MSEC XBRL filing
Cost of revenue (YoY) (2025-10-31 vs 2024-10-31): -12.9%Derived (calculated)
EPS (diluted) (YoY) (2025-10-31 vs 2024-10-31): 88.2%Derived (calculated)
Revenue (YoY) (2025-10-31 vs 2024-10-31): -5.3%Derived (calculated)
Capex (YoY) (2025-10-31 vs 2024-10-31): -95.8%Derived (calculated)
Gross margin (FY 2025-10-31): 32.3%Derived (calculated)
Operating income (YoY) (2025-10-31 vs 2024-10-31): 50.5%Derived (calculated)
Operating cash flow (YoY) (2025-10-31 vs 2024-10-31): 62.1%Derived (calculated)
Net income (YoY) (2025-10-31 vs 2024-10-31): 87.1%Derived (calculated)
Gross profit (YoY) (2025-10-31 vs 2024-10-31): 15.7%Derived (calculated)
Net margin (FY 2025-10-31): -1.1%Derived (calculated)
Net income (annual): USD -100.46KSEC XBRL filing
Cost of revenue (annual): USD 6.09MSEC XBRL filing
Operating cash flow (annual): USD -214.89KSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-04-30EARNINGSQuarterly results — Q1 2026 Revenue USD 5.0M · Net USD 0.3M

2026-01-31EARNINGSQuarterly results — Q4 2025 Revenue USD 2.3M · Net USD 0.0M

2026-01-31EARNINGSQuarterly results — Q4 2025

2025-10-31EARNINGSQuarterly results — Q3 2025

2025-10-31EARNINGSAnnual results — FY 2025 Revenue USD 9.0M · Net USD -0.1M

2024-10-31EARNINGSAnnual results — FY 2024 Revenue USD 9.5M · Net USD -0.8M

2023-10-31EARNINGSAnnual results — FY 2023 Revenue USD 17.0M · Net USD 1.3M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread